Ivarmacitinib Eased Refractory PCA: Case Report

Share

1

A 65-year-old man with refractory primary cutaneous amyloidosis showed rapid improvement after off-label treatment with ivarmacitinib.
2

The patient experienced significant pruritus relief and lesion improvement within one month of starting ivarmacitinib.
3

Histopathologic examination confirmed the diagnosis of primary cutaneous amyloidosis, showing characteristic amyloid deposits.
4

Ivarmacitinib, a selective JAK1 inhibitor, may target multiple inflammatory pathways involved in pruritus and T helper 2 inflammation.
5

The study highlights the potential of ivarmacitinib for treating isolated primary cutaneous amyloidosis, warranting further research.